Bioassays for Quality Control of Cell & Gene Therapy Products

Size: px
Start display at page:

Download "Bioassays for Quality Control of Cell & Gene Therapy Products"

Transcription

1 Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015

2 CTL019 Introduction CARTs = Chimeric Antigen Receptor transduced T cells CART19 = T cells engineered to express CD19 specific CAR Chimeric protein consists of recognition domain of anti- CD19 antibody (scfv) and intracellular CD3ζ and 4-1BB signaling domains MHC-independent, every surface molecule is a target Autologous product 2 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

3 CTL019 Introduction The chimeric antigen receptor consists of T- cell activation domains coupled to anti-cd19 single-chain variable fragments The intracellular T-cell receptor CD3-zeta chain signaling domain induces T-cell activation The CD137 (4-1BB) co-stimulatory domain enhances the cytolytic function of T cells and T-cell mediated responses The CD137 (4-1BB) domain impacts in vivo persistence by preferentially expanding memory cytotoxic lymphocytes and facilitating survival of memory cells Anti-CD19 antibody fragments bind to CD19- expressing cancer cells. The activated T cells are thus able to kill tumor cells in an antigen-dependent manner 3 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

4 CTL019 Overview of CTL019 Manufacturing Leukapheresis: The patient s own T cells are harvested T cells are activated and genetically transduced ex vivo with a lentiviral vector encoding the anti-cd19 chimeric antigen receptor (CAR) Chemotherapy: patient may receive a preparative lymphodepleting regimen before T cell infusion Slide adapted from K Walker CTL019 cells are re-infused into the patient where they expand and target CD19+ cells for destruction 4 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

5 CTL019 T cells Mode of Action Recognition of a common protein (CD19) by chimeric antigen receptor (CAR) Signaling through CD3 intracellular pathway Activation of Th and CTL responses - Expansion of the cells - High Cytotoxic Granule content - Strong expression of cytotoxic agents (FasL, IFN-g) - High expression potential of necessary cytokines / chemokines Cartellieri M, J Biomed Biotech CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

6 T cell activation a multifaceted process Cytokine production initiated, e.g. IFNγ, TNFα, IL-2, IL-6 Upregulation of surface marker expression, e.g. CD25, Fas, CD137 Shed surface receptors (e.g. CD25, Fas, CD137) and ligands (e.g. Fas ligand) T cells may Proliferate Kill targets Some/all of the above in sequence/ simultaneously 6

7 Functional bioassay for CTL019 Requirements Potency assays should be Simple reflecting potential Mode of Action (MoA) accurate, precise, robust and transferable be validated acc. to GMP 7 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

8 Functional potency bioassay for CART19 in vitro model of mode of action T cell (patient or reference) Cytokines / chemokines CART19 CD19 CD19+ cell cytotoxic granules Incubate Potential readouts 8 Cytotoxicity, apoptosis Degranulation markers by FACS (CD107a) Cytotoxic granule release (Perforin, Granzyme B,...) Cytokine release T cell activation (CD25, FasL)

9 Screening for readout Luminex CTL019 product was incubated with CD19 expressing cells (target) or control cells A 1:1 ratio of effector cells to target cells were incubated for 0, 6, and 20 hours. Culture supernatants were analyzed using a 17-plex Luminex kit. Conclusion Cytokine expression was specific to the co-incubation of CTL019 product and target cells. Cytokine (pg) Time Hrs 9 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

10 Potency bioassay for CART19 Cytokine release by ELISA Coculture with target cells Representative cytokine for T cell activation Cytokine readout (ELISA) Readout by commercial kit, relatively easy to use Reproducible, robust, and antigen-specific production linked to mechanism of action Shows early potential to distinguish responding from non-responding products 10 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

11 Final Assay Layout Cytokine release by ELISA Potency test: Coculture Product cells (50.000) CD19 expressing cells (stabily transfected) Controls (system suitability) Pos control: - Product cells (50.000) - PMA/Ionomycin Negative control: - Product cells (50.000) - Target cells expressing irrelevant protein Readout: Elisa for cytokine Acceptance criteria: Product exposed to CD19+ cells must show >5* negative control read 11 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

12 Validation: Intermediate Precision Intermediate precision improvement Three samples, four operators. Each operator worked independently Cell count and viability with Multisizer 4 and microscopy CD19 stimulated 4 Samples, 4 operators Each operator worked independently NC200 used for cell counts and viability CD19 stimulated pg/ml Sample 1 Op.1 Op.2 Op.3 CV 39.3% Sample 2 Sample 3 Op.1 Op.2 Op.3 Op.1 Op.2 Op.3 CV 34.2% CV 50.8% pg/ml Sample 1 Sample 2 Op.1 Op.2 Op.3 Op.4 Op.1 Op.2 Op.3 Op.4 CV 10.4% CV 6.9% Conclusion Changing from conventional viability and cell count (Trypan Blue) to automated fluorescent cell count improved int. precision from 50.8% (inacceptable) to 10.4% (Acceptable) 12 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

13 Linearity: number of target cells 50,000 CTL019 cells plated in co-culture with different numbers of target cells (12, ,000). Conclusion Linear correlation between effector and target cells 13 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

14 Linear response to stimulation by increasing numbers of CTL019 cells Transduced and non-transduced cells from the same donors were plated in different ratio with the total number of 50,000 cells per well. Conclusion Linear correlation between effector and target cells 14 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

15 Robustness, Cell Hold at 37C Pre-plating of cells Cells were thawed and held at 37C for various times Conclusion CTL019 cells can be held for upto 6 hours before co-culture Target cells can be held for upto 24 hours before co-culture 15 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

16 Robustness, Supernatant Hold Supernatant hold before freezing and after thaw Supernatant from CD19 stimulated co-cultures was harvested and held in room temperature before and after freezing. Conclusion Supernant can be held for upto 3 hours before freeze Supernant can be held for upto 24 hours after thaw 16 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

17 Characterization is key Future developments for Potency and Characterization Optimization of functional assay: Replace target cells with standardized CD19 source to reduce biological variation - (immobilized Rec. CD19 / activating antibody) Additional assay: Killing of CD19 expressing target cells Proliferation of CTL019 cells after stimulation with CD19 Extensive Phenotypic characterization of the T-cell populations 17 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

18 Thank you! Acknowledgements: Carlos Romero Therese Vallerskog Tamika Mayse-Webb Dirk Haubert Margit Jeschke Stefan Wildt Novartis Campus, Basel 18 CASS Bioassay 2015 Erik Rutjens 23MAR15 CTL019 Bioassay Business Use Only

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines

More information

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?

More information

Immunotherapy on the Horizon: Adoptive Cell Therapy

Immunotherapy on the Horizon: Adoptive Cell Therapy Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest

More information

CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris

CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION

More information

Micro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier

Micro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier Micro 204 Cytotoxic T Lymphocytes (CTL) Lewis Lanier Lewis.Lanier@ucsf.edu Lymphocyte-mediated Cytotoxicity CD8 + αβ-tcr + T cells CD4 + αβ-tcr + T cells γδ-tcr + T cells Natural Killer cells CD8 + αβ-tcr

More information

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU Cellular Immune response Jianzhong Chen, Ph.D Institute of immunology, ZJU Concept of adaptive immune response T cell-mediated adaptive immune response I. Concept of immune response A collective and coordinated

More information

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard

More information

Automated manufacture of T-cell immunotherapies using gamma retroviral transduction. Lee Markwick, PhD. AMC, Manchester March 2018

Automated manufacture of T-cell immunotherapies using gamma retroviral transduction. Lee Markwick, PhD. AMC, Manchester March 2018 Automated manufacture of T-cell immunotherapies using gamma retroviral transduction Lee Markwick, PhD AMC, Manchester March 2018 Automated generation of CAR T cells Starting material d0 T cell enrichment

More information

TCR, MHC and coreceptors

TCR, MHC and coreceptors Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed

More information

ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy

ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy

More information

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY The recognition of specific antigen by naïve T cell induces its own activation and effector phases. T helper cells recognize peptide antigens through

More information

T cell-mediated immunity

T cell-mediated immunity T cell-mediated immunity Overview For microbes within phagosomes in phagocytes.cd4+ T lymphocytes (TH1) Activate phagocyte by cytokines studies on Listeria monocytogenes For microbes infecting and replicating

More information

Abstract #163 Michael Kalos, PhD

Abstract #163 Michael Kalos, PhD LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract

More information

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

chapter 17: specific/adaptable defenses of the host: the immune response

chapter 17: specific/adaptable defenses of the host: the immune response chapter 17: specific/adaptable defenses of the host: the immune response defense against infection & illness body defenses innate/ non-specific adaptable/ specific epithelium, fever, inflammation, complement,

More information

Supplemental Figure 1. CD69 antigen-response curves of CAR engrafted Jurkat T cells. Supplemental Figure 2.

Supplemental Figure 1. CD69 antigen-response curves of CAR engrafted Jurkat T cells. Supplemental Figure 2. Supplemental Figure 1. CD69 antigen-response curves of CAR engrafted Jurkat T cells. To evaluate the antigen sensitivity of mutant CARs transduced Jurkat T cells were stimulated with varying concentrations

More information

Induction and Clearance of Latent HIV Infection:

Induction and Clearance of Latent HIV Infection: 214 Towards an HIV Cure symposium Melbourne Induction and Clearance of Latent HIV Infection: an Ex-Vivo Assessment of Immune Effectors using Cells from ART-treated Patients DM Margolis 1, C Garrido 1,

More information

NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections

NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor

More information

supplemental Figure 1

supplemental Figure 1 supplemental Figure 1 A T cell T1 anti-ny-eso-117-16/hla-a*:1 CDζ CH/CH scfv B T cell T1 anti-ny-eso-117-16/hla-a*:1 CDζ CH/CH scfv C T cell BW1/6 anti-cea CDζ CH/CH scfv supplemental Figure 1.79.9.87

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.

More information

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al. Clin Cancer Res

More information

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation

More information

BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective

BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective CASSS Bioassays May 09, 2017 Tara Stauffer 1 Overview Introduction: Cell-based bioassays in IO product development Immuno-Oncology (IO)

More information

Supplemental Methods. CD107a assay

Supplemental Methods. CD107a assay Supplemental Methods CD107a assay For each T cell culture that was tested, two tubes were prepared. One tube contained BCMA-K562 cells, and the other tube contained NGFR-K562 cells. Both tubes contained

More information

Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics. Charles Q. Morris MBChB MRCP(UK)

Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics. Charles Q. Morris MBChB MRCP(UK) Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics Charles Q. Morris MBChB MRCP(UK) 1 Enadenotucirev (EnAd): Developed using directed evolution EnAd Start

More information

Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS

Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS LECTURE: 14 Title: NATURAL KILLER CELL FUNCTIONS AND SURFACE RECEPTORS LEARNING OBJECTIVES: The student should be able to: Describe the general morphology of the NK-cells. Enumerate the different functions

More information

CD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways

CD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways CD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways Laura Strauss, Christoph Bergmann, Theresa L. Whiteside University

More information

Effector Mechanisms of Cell-Mediated Immunity

Effector Mechanisms of Cell-Mediated Immunity Effector Mechanisms of Cell-Mediated Immunity Dr. Julia Rempel Section of Hepatology 789-3825 jdrempel@cc.umanitoba.ca 804D JBRC Topics: I. Types of Cell-Mediated Immunity II. Migration of Effector T Lymphocytes

More information

Engineered TCR and CAR Immunotherapeutics 2015:

Engineered TCR and CAR Immunotherapeutics 2015: : A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs and CTLs released by La Merie Publishing on March 10, 2015 La Merie Publishing

More information

T cell and Cell-mediated immunity

T cell and Cell-mediated immunity T cell and Cell-mediated immunity Lu Linrong ( 鲁林荣 ) PhD Laboratory of Immune Regulation Institute of Immunology Zhejiang University, it School of Medicine i Medical Research Building B815-819 Email: Lu.Linrong@gmail.com

More information

Adaptive immune responses: T cell-mediated immunity

Adaptive immune responses: T cell-mediated immunity MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,

More information

CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION

CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION Justin Kline 1, Long Zhang 1, and Thomas F. Gajewski 1,2 Departments

More information

C. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.

C. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC. Immunology - Problem Drill 13: T- Cell Mediated Immunity Question No. 1 of 10 1. During Antibody-dependent cell mediated cytotoxicity (ADCC), the antibody acts like a bridge between the specific antigen

More information

Adaptive (acquired) immunity. Professor Peter Delves University College London

Adaptive (acquired) immunity. Professor Peter Delves University College London Adaptive (acquired) immunity Professor Peter Delves University College London p.delves@ucl.ac.uk Haematopoiesis Haematopoiesis Lymphocytes = adaptive response Recognition of pathogens by adaptive cells,

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke,. CONTRACTING ORGANIZATION: Johns Hopkins

More information

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,

More information

DEVELOPMENT OF CELLULAR IMMUNOLOGY

DEVELOPMENT OF CELLULAR IMMUNOLOGY DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer

More information

Bioactivity Assays: Putting the Puzzle Together

Bioactivity Assays: Putting the Puzzle Together Bioactivity Assays: Putting the Puzzle Together Dr. Ulrike Herbrand Department for Biosafety & Bioassay Services Charles River Biologics Testing Solutions Outline General Remarks MoA reflecting bioassays

More information

Supplementary Data Table of Contents:

Supplementary Data Table of Contents: Supplementary Data Table of Contents: - Supplementary Methods - Supplementary Figures S1(A-B) - Supplementary Figures S2 (A-B) - Supplementary Figures S3 - Supplementary Figures S4(A-B) - Supplementary

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

Yescarta (axicabtagene ciloleucel)

Yescarta (axicabtagene ciloleucel) Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider

More information

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus T cell precursors migrate from the bone marrow via the blood to the thymus to mature 1 2 The cellular organization of the thymus The proportion of thymus that produces T cells decreases with age 3 4 1

More information

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009 T Cell Activation Patricia Fitzgerald-Bocarsly March 18, 2009 Phases of Adaptive Immune Responses Phases of T cell responses IL-2 acts as an autocrine growth factor Fig. 11-11 Clonal Expansion of T cells

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

Immunotherapy of Prostate Cancer

Immunotherapy of Prostate Cancer Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines

More information

Third line of Defense

Third line of Defense Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)

More information

Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways

Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways Shihua Lin, PhD. Senior Scientist Analytical Biotechnology Development, MedImmune

More information

ILC1 and ILC3 isolation and culture Following cell sorting, we confirmed that the recovered cells belonged to the ILC1, ILC2 and

ILC1 and ILC3 isolation and culture Following cell sorting, we confirmed that the recovered cells belonged to the ILC1, ILC2 and Supplementary Methods and isolation and culture Following cell sorting, we confirmed that the recovered cells belonged to the, ILC2 and subsets. For this purpose we performed intracellular flow cytometry

More information

A Novel Class of Living Medicines

A Novel Class of Living Medicines A Novel Class of Living Medicines Synthetic Biotic TM medicines to perform and deliver critical therapeutic functions to treat diseases throughout the body Using Synthetic Biotic Medicines to Activate

More information

Adaptive Immunity: Specific Defenses of the Host

Adaptive Immunity: Specific Defenses of the Host 17 Adaptive Immunity: Specific Defenses of the Host SLOs Differentiate between innate and adaptive immunity, and humoral and cellular immunity. Define antigen, epitope, and hapten. Explain the function

More information

Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples

Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples ISCT North America 216 Regional Meeting Nadine Mockel-Tenbrinck Miltenyi Biotec GmbH Macrophage Tumour

More information

Tonic CAR signaling in T cells:

Tonic CAR signaling in T cells: Tonic CAR signaling in T cells: toxicities and ways to manage Max Mamonkin, PhD CAR-TCR Summit 9/6/217 Boston, MA CAR signaling Antige n Target cell CAR Signal 2 T cell Signal 1 Clustering Signaling Tonic

More information

REDIRECTING T CELL SPECIFICITY TO IGE-EXPRESSING B CELL FOR THE MANAGEMENT OF SEVERE ALLERGIC ASTHMA. Adebomi O. Adejuwon

REDIRECTING T CELL SPECIFICITY TO IGE-EXPRESSING B CELL FOR THE MANAGEMENT OF SEVERE ALLERGIC ASTHMA. Adebomi O. Adejuwon REDIRECTING T CELL SPECIFICITY TO IGE-EXPRESSING B CELL FOR THE MANAGEMENT OF SEVERE ALLERGIC ASTHMA by Adebomi O. Adejuwon A thesis submitted to the Faculty of the University of Delaware in partial fulfillment

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

Controlling cell-based bioassay performance through controlled preparation of bioassayready

Controlling cell-based bioassay performance through controlled preparation of bioassayready Controlling cell-based bioassay performance through controlled preparation of bioassayready cells Teresa Surowy September 2013 Promega Corporation Introduction The importance of cell-based bioassays and

More information

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy

More information

Supplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood

Supplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood Antibody-mediated depletion of CD19-CAR T cells Supplemental 1 Supplemental Materials Supplemental Figure 1. Supplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood cells were

More information

Reporter Gene Immunotherapy Bioassays

Reporter Gene Immunotherapy Bioassays Reporter Gene Immunotherapy Bioassays Expand the Tool Box for Drug Development in Individual and Combination Immunotherapy Jey Cheng, Ph.D. 215. BEBPA Bioassay Conference September 3, 216 Presentation

More information

T cell and Cell-mediated immunity

T cell and Cell-mediated immunity T cell and Cell-mediated immunity ( 第十章 第十二章第十二章 ) Lu Linrong ( 鲁林荣 ) PhD Laboratory of Immune Regulation Institute of Immunology Zhejiang University, School of Medicine Medical Research Building B815-819

More information

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205 AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING

More information

Chapter 17B: Adaptive Immunity Part II

Chapter 17B: Adaptive Immunity Part II Chapter 17B: Adaptive Immunity Part II 1. Cell-Mediated Immune Response 2. Humoral Immune Response 3. Antibodies 1. The Cell-Mediated Immune Response Basic Steps of Cell-Mediated IR 1 2a CD4 + MHC cl.

More information

Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant

Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179

More information

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution

More information

Assays for Immuno-oncology Research Real-time automated measurements of immune and tumor cell dynamics within your incubator

Assays for Immuno-oncology Research Real-time automated measurements of immune and tumor cell dynamics within your incubator INCUCYTE LIVE-CELL ANALYSIS SYSTEM Assays for Immuno-oncology Research Real-time automated measurements of immune and tumor cell dynamics within your incubator See what your cells are doing and when they

More information

CAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability. Julie M. Vose, MD, MBA

CAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability. Julie M. Vose, MD, MBA CAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability Julie M. Vose, MD, MBA Relevant Disclosures Research Funding: Kite Pharma/Gilead, JUNO/Celgene, Novartis Honorarium/Ad Boards: Novartis,

More information

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM. !! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)

More information

Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies

Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies After decades of investigation establishing principles in

More information

HTRF MEASUREMENT OF CYTOKINE RELEASE FROM FRESH BLOOD SAMPLES

HTRF MEASUREMENT OF CYTOKINE RELEASE FROM FRESH BLOOD SAMPLES HTRF MEASUREMENT OF CYTOKINE RELEASE FROM FRESH BLOOD SAMPLES APPLICATION NOTE ABSTRACT Cisbio offers a comprehensive line of HTRF cytokine assays to investigate the functional response of immune cells.

More information

Primer on Adoptive T cell Therapy. Saar Gill, MD, PhD University of Pennsylvania

Primer on Adoptive T cell Therapy. Saar Gill, MD, PhD University of Pennsylvania Primer on Adoptive T cell Therapy Saar Gill, MD, PhD University of Pennsylvania Presenter Disclosure Information Saar Gill The following relationships exist related to this presentation: Novartis, Research

More information

Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin

Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin Abhi Saharia, Ph. D. Director of Marketing Bioassays in Biologics Development Research

More information

FOR OPTIMAL GUT HEALTH KEMIN.COM/GUTHEALTH

FOR OPTIMAL GUT HEALTH KEMIN.COM/GUTHEALTH FOR OPTIMAL GUT HEALTH KEMIN.COM/GUTHEALTH ALETA A SOURCE OF 1,3-BETA GLUCANS Aleta is highly bioavailable, offering a concentration greater than 5% of 1,3-beta glucans. Aleta provides a consistent response

More information

The development of T cells in the thymus

The development of T cells in the thymus T cells rearrange their receptors in the thymus whereas B cells do so in the bone marrow. The development of T cells in the thymus The lobular/cellular organization of the thymus Immature cells are called

More information

The Adaptive Immune Response: T lymphocytes and Their Functional Types *

The Adaptive Immune Response: T lymphocytes and Their Functional Types * OpenStax-CNX module: m46560 1 The Adaptive Immune Response: T lymphocytes and Their Functional Types * OpenStax This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution

More information

Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression

Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression Jarad J Wilson, Ph.D. Technical Support & Marketing Specialist Ruo-Pan Huang, MD, Ph.D. Founder and CEO What are Antibody Arrays?

More information

Supplemental Information. Augmentation of Antitumor Immunity by Human. and Mouse CAR T Cells Secreting IL-18

Supplemental Information. Augmentation of Antitumor Immunity by Human. and Mouse CAR T Cells Secreting IL-18 Cell Reports, Volume 20 Supplemental Information Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18 Biliang Hu, Jiangtao Ren, Yanping Luo, Brian Keith, Regina M. Young, John

More information

Designing clinical trials with BiTE antibody constructs by leveraging from nonclinical data. Benno Rattel Biologics Congress Berlin, 2015

Designing clinical trials with BiTE antibody constructs by leveraging from nonclinical data. Benno Rattel Biologics Congress Berlin, 2015 Designing clinical trials with BiTE antibody constructs by leveraging from nonclinical data Benno Rattel Biologics Congress Berlin, 215 1 BiTE Antibody Contructs are Designed to Function as a Bridge between

More information

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

Engineering chimeric antigen receptor-t cells for cancer treatment

Engineering chimeric antigen receptor-t cells for cancer treatment Ye et al. Molecular Cancer (2018) 17:32 https://doi.org/10.1186/s12943-018-0814-0 REVIEW Engineering chimeric antigen receptor-t cells for cancer treatment Baixin Ye 1, Creed M. Stary 2, Xuejun Li 3, Qingping

More information

LAB 1, Immunology. Laboratory manual Immunology and Infection Biology Biomedicine course Autumn 2007

LAB 1, Immunology. Laboratory manual Immunology and Infection Biology Biomedicine course Autumn 2007 LAB 1, Immunology Laboratory manual Immunology and Infection Biology Biomedicine course Autumn 2007 QUANTIFICATION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY AND DETECTION OF FAS/TRAILR INDUCED APOPTOSIS RESPONSIBLE:

More information

Defensive mechanisms include :

Defensive mechanisms include : Acquired Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated immunity Humoral immunity Two mechanisms 1) Humoral

More information

New insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre

New insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures

More information

Melanoma Bridge Meeting

Melanoma Bridge Meeting Melanoma Bridge Meeting Improving Adoptive Immune Therapy with Genetically Engineered T cells David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH 3 December 2015 Adoptive T Cell Therapy: Dose

More information

Engineering an in vitro human immune system for rapid vaccine evaluation

Engineering an in vitro human immune system for rapid vaccine evaluation Engineering an in vitro human immune system for rapid vaccine evaluation William Warren, Ph.D. VaxDesign Corporation Orlando, FL 32826 wwarren@vaxdesign.com www.vaxdesign.com 1 MIMIC Technology Overview

More information

Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers

Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for

More information

The Emergence of Universal Immune Receptors for Highly Personalized T cell Therapy

The Emergence of Universal Immune Receptors for Highly Personalized T cell Therapy The Emergence of Universal Immune Receptors for Highly Personalized T cell Therapy INNOVATIVE APPROACHES TO T CELL BASED THERAPIES Daniel Powell Ph.D. Dept of Pathology and Laboratory Medicine Abramson

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Figure 1. NKT ligand-loaded tumour antigen-presenting B cell- and monocyte-based vaccine induces NKT, NK and CD8 T cell responses. (A) The cytokine profiles of liver

More information

NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity

NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging

More information

I. Critical Vocabulary

I. Critical Vocabulary I. Critical Vocabulary A. Immune System: a set of glands, tissues, cells, and dissolved proteins that combine to defend against non-self entities B. Antigen: any non-self chemical that triggers an immune

More information

ImmunoTools special Award 2014

ImmunoTools special Award 2014 ImmunoTools special Award 2014 Davide Ferrari, PhD University of Ferrara, Department of Morphology, Surgery and Experimental Medicine. Section of Pathology, Oncology and Exper. Biology via L. Borsari 46,

More information

Lecture 4. T lymphocytes

Lecture 4. T lymphocytes Lecture 4 T lymphocytes Objectives Mention the types of T cells List the Types of T helper cell (CD4+) Discuss the Activation of T cells Define Interleukins Distinguish the Super Ag from ordinary Ag Show

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice

More information

Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL

Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL Diana Schreier, Pharm.D., M.B.A. Pharmacy Grand Rounds October 17, 2017 2017 MFMER

More information

Supplemental Methods In vitro T cell assays Inhibition of perforin- and FasL-mediated cytotoxicity Flow Cytometry

Supplemental Methods In vitro T cell assays Inhibition of perforin- and FasL-mediated cytotoxicity Flow Cytometry Supplemental Methods In vitro T cell assays Cell lines Jurkat (ATCC #TIB-152), CCRF-CEM (ATCC #CCL-119), MOLT-4 (ATCC #CRL- 1582), Hut 78 (ATCC #TIB-161), SupT1 (ATCC #CRL-1942), Raji (ATCC #CCL-86) and

More information

NK cell flow cytometric assay In vivo DC viability and migration assay

NK cell flow cytometric assay In vivo DC viability and migration assay NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with

More information

Page 4: Antigens: Self-Antigens The body has a vast number of its own antigens called self-antigens. These normally do not trigger immune responses.

Page 4: Antigens: Self-Antigens The body has a vast number of its own antigens called self-antigens. These normally do not trigger immune responses. Common Characteristics of B and T Lymphocytes Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com). Page 1: Introduction While B and T lymphocytes

More information

Supporting Information

Supporting Information Supporting Information Bellora et al. 10.1073/pnas.1007654108 SI Materials and Methods Cells. NK cells purified from peripheral blood mononuclear cells (PBMC) of healthy donors (Human NK Cell Isolation

More information

Immunology - Lecture 2 Adaptive Immune System 1

Immunology - Lecture 2 Adaptive Immune System 1 Immunology - Lecture 2 Adaptive Immune System 1 Book chapters: Molecules of the Adaptive Immunity 6 Adaptive Cells and Organs 7 Generation of Immune Diversity Lymphocyte Antigen Receptors - 8 CD markers

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Chandran SS, Somerville RPT, Yang JC, et al.

More information

Advances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014

Advances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014 Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus

More information